JP2023027269A5 - - Google Patents

Download PDF

Info

Publication number
JP2023027269A5
JP2023027269A5 JP2022199122A JP2022199122A JP2023027269A5 JP 2023027269 A5 JP2023027269 A5 JP 2023027269A5 JP 2022199122 A JP2022199122 A JP 2022199122A JP 2022199122 A JP2022199122 A JP 2022199122A JP 2023027269 A5 JP2023027269 A5 JP 2023027269A5
Authority
JP
Japan
Prior art keywords
purin
cyclohexanecarboxamide
ylamino
chloro
difluorophenylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022199122A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023027269A (ja
Filing date
Publication date
Priority claimed from JP2017538172A external-priority patent/JP6884701B2/ja
Application filed filed Critical
Publication of JP2023027269A publication Critical patent/JP2023027269A/ja
Publication of JP2023027269A5 publication Critical patent/JP2023027269A5/ja
Pending legal-status Critical Current

Links

JP2022199122A 2014-10-06 2022-12-14 置換アミノプリン化合物、その組成物、及びそれによる治療の方法 Pending JP2023027269A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462060339P 2014-10-06 2014-10-06
US62/060,339 2014-10-06
JP2017538172A JP6884701B2 (ja) 2014-10-06 2015-10-05 置換アミノプリン化合物、その組成物、及びそれによる治療の方法
JP2019182133A JP6987823B2 (ja) 2014-10-06 2019-10-02 置換アミノプリン化合物、その組成物、及びそれによる治療の方法
JP2021195105A JP7196270B2 (ja) 2014-10-06 2021-12-01 置換アミノプリン化合物、その組成物、及びそれによる治療の方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021195105A Division JP7196270B2 (ja) 2014-10-06 2021-12-01 置換アミノプリン化合物、その組成物、及びそれによる治療の方法

Publications (2)

Publication Number Publication Date
JP2023027269A JP2023027269A (ja) 2023-03-01
JP2023027269A5 true JP2023027269A5 (enExample) 2023-03-08

Family

ID=55632334

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017538172A Active JP6884701B2 (ja) 2014-10-06 2015-10-05 置換アミノプリン化合物、その組成物、及びそれによる治療の方法
JP2019182133A Active JP6987823B2 (ja) 2014-10-06 2019-10-02 置換アミノプリン化合物、その組成物、及びそれによる治療の方法
JP2021195105A Active JP7196270B2 (ja) 2014-10-06 2021-12-01 置換アミノプリン化合物、その組成物、及びそれによる治療の方法
JP2022199122A Pending JP2023027269A (ja) 2014-10-06 2022-12-14 置換アミノプリン化合物、その組成物、及びそれによる治療の方法

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2017538172A Active JP6884701B2 (ja) 2014-10-06 2015-10-05 置換アミノプリン化合物、その組成物、及びそれによる治療の方法
JP2019182133A Active JP6987823B2 (ja) 2014-10-06 2019-10-02 置換アミノプリン化合物、その組成物、及びそれによる治療の方法
JP2021195105A Active JP7196270B2 (ja) 2014-10-06 2021-12-01 置換アミノプリン化合物、その組成物、及びそれによる治療の方法

Country Status (28)

Country Link
US (8) US9512124B2 (enExample)
EP (2) EP3204386B1 (enExample)
JP (4) JP6884701B2 (enExample)
KR (2) KR20230035424A (enExample)
CN (2) CN113248506A (enExample)
AR (2) AR102171A1 (enExample)
AU (2) AU2015328414B2 (enExample)
CA (1) CA2963639C (enExample)
CL (1) CL2017000820A1 (enExample)
CO (1) CO2017003838A2 (enExample)
CY (1) CY1124173T1 (enExample)
DK (1) DK3204386T3 (enExample)
EA (1) EA201790779A1 (enExample)
EC (1) ECSP17026210A (enExample)
ES (2) ES2980464T3 (enExample)
HR (1) HRP20210656T1 (enExample)
HU (1) HUE054694T2 (enExample)
IL (2) IL251566B (enExample)
LT (1) LT3204386T (enExample)
MX (2) MX388321B (enExample)
PL (1) PL3204386T3 (enExample)
PT (1) PT3204386T (enExample)
RS (1) RS61884B1 (enExample)
SG (2) SG10202009598VA (enExample)
SI (1) SI3204386T1 (enExample)
SM (1) SMT202100302T1 (enExample)
TW (1) TW201629063A (enExample)
WO (1) WO2016057370A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS61884B1 (sr) * 2014-10-06 2021-06-30 Signal Pharm Llc Supstituisana aminopurinska jedinjenja, kompozicije koje ih sadrže i postupci za lečenje u kojima se koriste
WO2016100308A1 (en) 2014-12-16 2016-06-23 Signal Pharmaceuticals, Llc Methods for measurement of inhibition of c-jun n-terminal kinase in skin
US20180022710A1 (en) 2015-01-29 2018-01-25 Signal Pharmaceuticals, Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
KR102654709B1 (ko) 2015-03-18 2024-04-03 브리스톨-마이어스 스큅 컴퍼니 치환된 트리시클릭 헤테로시클릭 화합물
MX2017011433A (es) 2015-03-18 2017-11-10 Bristol Myers Squibb Co Compuestos heterociclicos triciclicos utiles como inhibidores del factor de necrosis tumoral (tnf).
EA201792054A1 (ru) 2015-03-18 2018-01-31 Бристол-Майерс Сквибб Компани Гетероциклические соединения, применимые в качестве ингибиторов tnf
EP3795553B1 (en) 2015-07-24 2024-05-15 Celgene Corporation Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
KR102679517B1 (ko) 2015-08-03 2024-06-27 브리스톨-마이어스 스큅 컴퍼니 Tnf 알파의 조정제로서 유용한 시클릭 화합물
SMT202100604T1 (it) * 2016-04-01 2021-11-12 Signal Pharm Llc (1s,4s)-4-(2-(((3s,4r)-3-fluorotetraidro-2h-piran-4-il)ammino)-8-((2,4,6-triclorofenil)ammino)-9h-purin-9-il)-1-metilcicloesano-1-carbossammide e metodi per il loro utilizzo
BR112018070163A2 (pt) * 2016-04-01 2019-01-29 Signal Pharm Llc compostos de aminopurina substituída, composições e métodos de tratamento
WO2017210408A1 (en) * 2016-06-02 2017-12-07 Celgene Corporation Animal and human anti-trypanosomonal and anti-leishmania agents
EP3464287B1 (en) * 2016-06-02 2022-06-08 Celgene Corporation Animal and human anti-malarial agents
KR20200062270A (ko) 2017-10-04 2020-06-03 셀진 코포레이션 시스-4-[2-{[(3s,4r)-3-플루오로옥산-4-일]아미노}-8-(2,4,6-트리클로로아닐리노)-9h-퓨린-9-일]-1-메틸시클로헥산-1-카르복스아미드의 조성물 및 이용 방법
JP2020536100A (ja) * 2017-10-04 2020-12-10 セルジーン コーポレイション シス−4−[2−{[(3s,4r)−3−フルオロキサン−4−イル]アミノ}−8−(2,4,6−トリクロロアニリノ)−9h−プリン−9−イル]−1−メチルシクロヘキサン−1−カルボキサミドの製造プロセス
CN115916747A (zh) * 2020-07-01 2023-04-04 四川海思科制药有限公司 一种并环杂环衍生物及其在医药上的应用
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
CN114478326B (zh) * 2022-01-21 2023-10-03 安徽宁亿泰科技有限公司 一种苯嘧磺草胺关键中间体的合成方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
FI109088B (fi) 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
US7672705B2 (en) * 2004-07-19 2010-03-02 Resonant Medical, Inc. Weighted surface-to-surface mapping
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7723340B2 (en) 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7759342B2 (en) * 2005-01-13 2010-07-20 Signal Pharmaceuticals, Llc Methods of treatment and prevention using haloaryl substituted aminopurines
US20090215744A1 (en) 2005-11-18 2009-08-27 Astrazeneca Ab Solid Formulations
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
KR20090084891A (ko) 2006-10-27 2009-08-05 시그날 파마소티칼 엘엘씨 4-[9-(테트라하이드로-퓨란-3-일)-8-(2,4,6-트리플루오로-페닐아미노)-9h-퓨린-2-일아미노]-사이클로헥산-1-올을 포함하는 고체 형태들, 이들의 조성물들 및 이들의 용도
ES2400006T3 (es) 2008-04-23 2013-04-04 Farmasierra Manufacturing, S.L. Formulación farmacéutica mejorada a base de ibuprofeno y codeína
WO2011071491A1 (en) 2009-12-09 2011-06-16 Signal Pharmaceuticals, Llc Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2, 4, 6- trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol
US8680076B2 (en) * 2010-10-25 2014-03-25 Signal Pharmaceuticals, Llc Methods of treatment, improvement and prevention using haloaryl substituted aminopurines
US8603527B2 (en) 2010-10-25 2013-12-10 Signal Pharmaceuticals, Llc Pharmaceutical formulations of a substituted diaminopurine
US20160082015A1 (en) 2013-04-18 2016-03-24 President And Fellows Of Harvard College Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
RS61884B1 (sr) * 2014-10-06 2021-06-30 Signal Pharm Llc Supstituisana aminopurinska jedinjenja, kompozicije koje ih sadrže i postupci za lečenje u kojima se koriste
SMT202100604T1 (it) 2016-04-01 2021-11-12 Signal Pharm Llc (1s,4s)-4-(2-(((3s,4r)-3-fluorotetraidro-2h-piran-4-il)ammino)-8-((2,4,6-triclorofenil)ammino)-9h-purin-9-il)-1-metilcicloesano-1-carbossammide e metodi per il loro utilizzo

Similar Documents

Publication Publication Date Title
JP2023027269A5 (enExample)
JP2017530199A5 (enExample)
RU2469032C2 (ru) Производные 2-(пиперидин-4-ил)-4-фенокси- или фениламинопиримидина в качестве ненуклеозидных ингибиторов обратной транскриптазы
HRP20210656T1 (hr) Supstituirani spojevi aminopurina, njihovi sastavi, te postupci liječenja istima
RU2373209C2 (ru) Пирролотриазиновые соединения как ингибиторы киназ
RU2017121958A (ru) Замещенные диаминокарбоксамидные и диаминокарбонитрильные производные пиримидинов, их композиции и способы лечения с их помощью
JP6411895B2 (ja) 治療活性化合物およびその使用方法
JP2012506446A5 (enExample)
JP5508265B2 (ja) 多発性硬化症の治療のための、スフィンゴシン1−ホスフェート(s1p)受容体に結合する6−アミノ−ピリミジン−4−カルボキサミド誘導体及び関連化合物
CN1823063B (zh) 作为磷酸二酯酶抑制剂的喹啉衍生物
JP2011518158A5 (enExample)
JP2018522823A5 (enExample)
JP2008509910A5 (enExample)
IL267743A (en) Mutant Isocetrate Dehydrogenase Suppressant Compounds, Preparations and Uses
CA2564355A1 (en) Protein kinase modulators and method of use
CA2582029A1 (en) Aryl nitrogen-containing bicyclic compounds and methods of use
JP2017529346A5 (enExample)
RU2005119151A (ru) Производные пиридазинона в качестве gsk-3бета-ингибиторов
JP2015529224A5 (enExample)
JP2013544893A5 (enExample)
JP6529492B2 (ja) 癌の処置のためのidh2突然変異体阻害剤としての2,4−または4,6−ジアミノピリミジン化合物
IL259975A (en) Pyridine compounds are converted to 4-phenyl as unsystematic trg5 agonists
JP2016518344A5 (enExample)
ZA200606880B (en) Diaminopyrimidines as P2X3 and P2X2/3 antagonists
RU2009148673A (ru) Производные пиразинона и их применение для лечения легочных заболеваний